Correlation Between Pharmaceuticals Ultrasector and Small-cap Growth

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pharmaceuticals Ultrasector and Small-cap Growth at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharmaceuticals Ultrasector and Small-cap Growth into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pharmaceuticals Ultrasector Profund and Small Cap Growth Profund, you can compare the effects of market volatilities on Pharmaceuticals Ultrasector and Small-cap Growth and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharmaceuticals Ultrasector with a short position of Small-cap Growth. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharmaceuticals Ultrasector and Small-cap Growth.

Diversification Opportunities for Pharmaceuticals Ultrasector and Small-cap Growth

0.67
  Correlation Coefficient

Poor diversification

The 3 months correlation between Pharmaceuticals and Small-cap is 0.67. Overlapping area represents the amount of risk that can be diversified away by holding Pharmaceuticals Ultrasector Pr and Small Cap Growth Profund in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Small Cap Growth and Pharmaceuticals Ultrasector is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharmaceuticals Ultrasector Profund are associated (or correlated) with Small-cap Growth. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Small Cap Growth has no effect on the direction of Pharmaceuticals Ultrasector i.e., Pharmaceuticals Ultrasector and Small-cap Growth go up and down completely randomly.

Pair Corralation between Pharmaceuticals Ultrasector and Small-cap Growth

Assuming the 90 days horizon Pharmaceuticals Ultrasector is expected to generate 2.74 times less return on investment than Small-cap Growth. In addition to that, Pharmaceuticals Ultrasector is 1.24 times more volatile than Small Cap Growth Profund. It trades about 0.02 of its total potential returns per unit of risk. Small Cap Growth Profund is currently generating about 0.07 per unit of volatility. If you would invest  7,902  in Small Cap Growth Profund on August 27, 2024 and sell it today you would earn a total of  1,200  from holding Small Cap Growth Profund or generate 15.19% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Pharmaceuticals Ultrasector Pr  vs.  Small Cap Growth Profund

 Performance 
       Timeline  
Pharmaceuticals Ultrasector 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Pharmaceuticals Ultrasector Profund are ranked lower than 5 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak basic indicators, Pharmaceuticals Ultrasector may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Small Cap Growth 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Small Cap Growth Profund are ranked lower than 7 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak basic indicators, Small-cap Growth may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Pharmaceuticals Ultrasector and Small-cap Growth Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pharmaceuticals Ultrasector and Small-cap Growth

The main advantage of trading using opposite Pharmaceuticals Ultrasector and Small-cap Growth positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharmaceuticals Ultrasector position performs unexpectedly, Small-cap Growth can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Small-cap Growth will offset losses from the drop in Small-cap Growth's long position.
The idea behind Pharmaceuticals Ultrasector Profund and Small Cap Growth Profund pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements